News

Abstracts will include updates on treatment for psoriatic arthritis, psoriasis, atopic dermatitis, and more.

Positioning your portfolio for price stability and growth.

New research by the National Eczema Association has revealed the importance of patient input into treatment decisions.

ICYMI, this week we had stories about adherence issues in acne treatment, shin guard dermatitis, atopic dermatitis in skin of color patients, clinical trial news from Arcutis Biotherapeutics, and more.

Domestic production to begin at Michigan-based pharmaceutical maker.

Emergency Use Authorization provides a 2-dose primary series given 3 weeks apart.

ICYMI, this week we had stories about psoriasis and tattoos, shin guard dermatitis, rosacea symptoms, a new treatment option for severe burns, and more.

Physicians groups, analysts, have praised insurance premium subsidies, Medicare drug cost caps.

MediWound’s new burn care therapy alleviates risks associated with surgical debridement.

ICYMI, this week we had stories about product recalls, FDA warning letters, pediatric atopic dermatitis, acne treatment, and more.

VYNE Therapeutics Inc. announced the results of study VY2021-01.

Amazon, Ariella Naturals, and Justified Laboratories received warning letters from the FDA.

Edgewell Personal Care Company issued a voluntary national recall of 3 collections of Banana Boat Hair & Scalp Sunscreen due to the presence of benzene.

White House ramps up efforts to fight outbreak.

ICYMI, this week we had stories about FDA approvals, biologics vs biosimilars, CTCL treatment, atopic dermatitis in patients with skin of color, and more.

Click to see a preview of what to expect this week.

ICYMI, this week we had stories about legal issues in practices, sustainable skin care, acne scar treatments, monkeypox, and more.

A healthy 14-year old boy was evaluated for an intensely pruritic shin rash that developed 2 weeks prior and had been treated with oral antibiotics for 10 days.

What we know about monkeypox in pregnancy, including treatment recommendations, vaccination, and postpartum care.

The decision comes following reports of 16,000 cases across 75 countries and territories around the world.

ICYMI, this week we had stories about skin cancer, FDA approvals, vitiligo, consumer trends, and more.

Click to see a preview of what to expect this week.

ICYMI, this week we had stories about atopic dermatitis, acne, psoriasis, consumer trends, and more.

Investigators suggest parents and clinicians should be mindful of children with suspected ACD with a history of exposure to jewelry, clothing, and belts with cobalt.

The groundbreaking approval of sirolimus topical gel brings relief to patients with facial angiofibroma related to tuberous sclerosis complex with the first FDA-approved topical treatment.

The increases had no impact on the efficacy of the drug and were rarely associated with symptoms or sequelae.

ICYMI, this week we had stories about the Society for Pediatric Dermatology 2022 Meeting, FDA updates, mental health, and more.

Verrica is complying with the FDA through 3 Complete Response Letters to achieve the first FDA-approved treatment of molluscum contagiosum.

This week's edition of the Mainstream Patient features stories about abortions, spray sunscreen, tinted moisturizers, and more.

ICYMI, this week we had stories about pediatric atopic dermatitis, managing complex diseases, Medicare, and more.